Hypertrophic cardiomyopathy in myosin-binding protein C (MYBPC3) Icelandic founder mutation carriers

ObjectiveThe myosin-binding protein C (MYBPC3) c.927-2A>G founder mutation accounts for >90% of sarcomeric hypertrophic cardiomyopathy (HCM) in Iceland. This cross-sectional observational study explored the penetrance and phenotypic burden among carriers of this single, prevalent founder mutat...

Descripción completa

Detalles Bibliográficos

Autores principales:	Javier Diez, Begoña López, Barry J Maron, Berglind Adalsteinsdottir, Michael Burke, Ragnar Danielsen, Petr Jarolim, Jonathan Seidman, Christine E. Seidman, Carolyn Y Ho, Gunnar Th Gunnarsson
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	BMJ Publishing Group 2020-06-01
Colección:	Open Heart
Acceso en línea:	https://openheart.bmj.com/content/7/1/e001220.full
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!